In monocytes, SARS-CoV-2 infection activates the NLRP3 inflammasome [283,284], suggesting that NLRP3 could be a marker of disease severity and a possible therapeutic target for COVID-19 [283,285]. This evidence concerns the gene NLRP3 and COVID-19.